Testosterone, 'gear,' and TRT: separating hype from hormone science

What's this video probably claiming?

Based on the hashtags #gear, #steroid, and #testostérone, this creator is almost certainly operating somewhere in the overlap between performance-enhancement culture and the growing TRT conversation online. Videos tagged this way typically make one or more of the following arguments: that testosterone is broadly safe or even beneficial for men who aren't clinically hypogonadal, that the medical system is too conservative with dosing thresholds, that 'optimizing' testosterone above the normal reference range produces meaningful physical or cognitive benefits, or that the line between prescribed TRT and performance-enhancing steroid use is arbitrary. Some creators in this space also present anecdotal self-experiments as evidence. With only 1.2K views and a handle like @testsubjects13, this reads more like a personal experimentation log than a clinical education channel, which raises its own reliability flags.

What does the science actually show?

Legitimate TRT is a well-studied intervention for men with confirmed hypogonadism, defined by the Endocrine Society as a total testosterone below 300 ng/dL combined with symptoms. A 2018 meta-analysis by Corona et al. in Sexual Medicine Reviews found that in genuinely hypogonadal men, TRT improved sexual function, mood, and lean mass. The Testosterone Trials (Snyder et al., 2016, NEJM), a set of seven coordinated RCTs, found modest improvements in sexual desire and physical capacity in older men with low testosterone. However, those same trials found no significant cognitive benefit and flagged a higher rate of noncalcified coronary artery plaque progression in the testosterone arm. The FDA requires testosterone products to carry labeling warnings about cardiovascular risk. Supraphysiological dosing, meaning taking enough testosterone to push serum levels well above the 900-1000 ng/dL upper end of normal, is a separate category with a much thinner and less reassuring evidence base.

Where does the social media noise diverge from clinical reality?

The 'gear' community and parts of the TRT-optimization space routinely present several ideas that don't hold up to scrutiny. First, the claim that any man with suboptimal energy or libido is a candidate for testosterone is not supported. A 2021 study by Handelsman in Andrology found that symptoms alone have poor specificity for true hypogonadism, and many men with 'low T symptoms' have testosterone in the normal range. Second, the framing of testosterone as simply 'replacing what you're missing' ignores that supraphysiological use suppresses endogenous production via the hypothalamic-pituitary-gonadal axis, which can persist after cessation. Third, the cardiovascular risk picture is genuinely uncertain. A 2023 RCT by Lincoff et al. in NEJM (the TRAVERSE trial) found no significant increase in major cardiovascular events at standard TRT doses in men with hypogonadism, but this does not generalize to bodybuilding-range dosing.

What should you actually know?

If you're considering testosterone therapy, the starting point is a properly collected morning total testosterone level, ideally confirmed on two separate draws, along with LH, FSH, and SHBG. A single low reading in isolation is not a diagnosis. Gel formulations (applied daily) and injectable esters like testosterone cypionate or enanthate (typically dosed weekly or biweekly) have different pharmacokinetic profiles, which affects both symptom management and monitoring needs. Standard replacement targets for symptomatic hypogonadism are generally in the mid-normal range, not the ceiling. Hematocrit rise is a real and dose-dependent risk: a 2016 review by Bachman et al. in Current Opinion in Endocrinology noted that injectable formulations produce greater hematocrit elevation than transdermal options. Anyone presented with a specific dosing protocol by a social media creator, rather than a prescribing clinician reviewing their actual labs, should treat that information with significant skepticism.